AU2013267209B2 - Modulation of hepatitis B virus cccDNA transcription - Google Patents

Modulation of hepatitis B virus cccDNA transcription Download PDF

Info

Publication number
AU2013267209B2
AU2013267209B2 AU2013267209A AU2013267209A AU2013267209B2 AU 2013267209 B2 AU2013267209 B2 AU 2013267209B2 AU 2013267209 A AU2013267209 A AU 2013267209A AU 2013267209 A AU2013267209 A AU 2013267209A AU 2013267209 B2 AU2013267209 B2 AU 2013267209B2
Authority
AU
Australia
Prior art keywords
group
hydrogen
inhibitor
alkyl
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013267209A
Other languages
English (en)
Other versions
AU2013267209A1 (en
Inventor
Harold R. Almond
Timothy M. Block
Jinhong Chang
Ju-Tao Guo
William A. Kinney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drexel University
Baruch S. Blumberg Institute
Original Assignee
BARUCH S BLUMBERG INST
Drexel University
Baruch S. Blumberg Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BARUCH S BLUMBERG INST, Drexel University, Baruch S. Blumberg Institute filed Critical BARUCH S BLUMBERG INST
Publication of AU2013267209A1 publication Critical patent/AU2013267209A1/en
Application granted granted Critical
Publication of AU2013267209B2 publication Critical patent/AU2013267209B2/en
Priority to AU2017202675A priority Critical patent/AU2017202675A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013267209A 2012-06-01 2013-05-31 Modulation of hepatitis B virus cccDNA transcription Ceased AU2013267209B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017202675A AU2017202675A1 (en) 2012-06-01 2017-04-21 Modulation of hepatitis b virus cccdna transcription

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654374P 2012-06-01 2012-06-01
US61/654,374 2012-06-01
PCT/US2013/043691 WO2013181584A2 (en) 2012-06-01 2013-05-31 Modulation of hepatitis b virus cccdna transcription

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017202675A Division AU2017202675A1 (en) 2012-06-01 2017-04-21 Modulation of hepatitis b virus cccdna transcription

Publications (2)

Publication Number Publication Date
AU2013267209A1 AU2013267209A1 (en) 2014-12-18
AU2013267209B2 true AU2013267209B2 (en) 2017-02-02

Family

ID=49674087

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013267209A Ceased AU2013267209B2 (en) 2012-06-01 2013-05-31 Modulation of hepatitis B virus cccDNA transcription
AU2017202675A Abandoned AU2017202675A1 (en) 2012-06-01 2017-04-21 Modulation of hepatitis b virus cccdna transcription

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017202675A Abandoned AU2017202675A1 (en) 2012-06-01 2017-04-21 Modulation of hepatitis b virus cccdna transcription

Country Status (13)

Country Link
US (3) US9623071B2 (enExample)
EP (1) EP2854832A4 (enExample)
JP (1) JP6431478B2 (enExample)
KR (1) KR101945578B1 (enExample)
CN (1) CN104507488A (enExample)
AU (2) AU2013267209B2 (enExample)
BR (1) BR112014029697A2 (enExample)
CA (1) CA2874828A1 (enExample)
HK (1) HK1208823A1 (enExample)
IL (1) IL235912A0 (enExample)
PH (1) PH12014502659A1 (enExample)
SG (1) SG11201407970VA (enExample)
WO (1) WO2013181584A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HK1215030A1 (zh) * 2012-11-09 2016-08-12 Indiana University Research And Technology Corporation 用於hbv組裝效應劑的替代用途
WO2014093709A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
JP6738728B2 (ja) 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
ES2777217T3 (es) 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
KR20160097338A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
CN105899658B (zh) 2013-12-12 2020-02-18 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
RU2711750C2 (ru) * 2014-06-20 2020-01-21 Дрексель Юнивёрсити Меченый антиген е гепаднавируса и его применение в скрининге противовирусных веществ
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
EP3929287A3 (en) 2015-06-18 2022-04-13 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017015451A1 (en) * 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR101771309B1 (ko) * 2015-07-24 2017-08-24 재단법인 목암생명과학연구소 B형 간염 바이러스의 ｃｃｃＤＮＡ 형성 억제용 약학 조성물
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
EP3468561A4 (en) 2016-06-10 2019-12-04 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
JP6811338B2 (ja) * 2016-12-13 2021-01-13 エーエム サイエンシーズ インコーポレイテッド Ｂ型肝炎の予防または治療用医薬組成物
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
WO2019110589A1 (en) * 2017-12-04 2019-06-13 F. Hoffmann-La Roche Ag Pyrrolo[2,3-b]pyrazine compounds as cccdna inhibitors for the treatment of hepatitis b virus (hbv) infection
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019113173A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
SG11202007097QA (en) 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019240503A1 (ko) * 2018-06-12 2019-12-19 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression
TW202024093A (zh) 2018-09-21 2020-07-01 美商安塔製藥公司 作為抗病毒劑之官能化雜環
CN112888480A (zh) * 2018-10-24 2021-06-01 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒疾病的新型三环化合物
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
TWI853940B (zh) 2019-05-31 2024-09-01 美商維拉克塔股份有限公司 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
JP2022550454A (ja) * 2019-10-02 2022-12-01 ユニバーシティ オブ ワシントン Ｂ型肝炎ウイルス感染の治療のための組成物及び方法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
JP2023538630A (ja) * 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
CN112274516B (zh) * 2020-10-26 2022-08-05 中山大学附属第三医院 一种新型含碘抗病毒药物
IT202100005054A1 (it) * 2021-03-04 2022-09-04 Azienda Ospedaliero Univ Di Parma Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051846A1 (en) * 2000-12-22 2002-07-04 Zee, Ok Pyo Apicidin-derivatives, their synthetic methods, and antitumor compositions containing the same
US20100009970A1 (en) * 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1126426-52-5; STN Entry Date 25 March 2009; Cyclo[L-alanyl-(2S)-2-amino-8-oxodecanoyl-L-tryptophyl-L-leucyl] *
CAS Registry Number 1126426-54-7; STN Entry Date 25 March 2009; Cyclo[L-alanyl-(2S)-2-amino-8-oxodecanoyl-D-tryptophyl-L-leucyl] *
CAS Registry Number 1126426-56-9; STN Entry Date 25 March 2009; Cyclo[L-alanyl-(2S)-2-amino-8-(hydroxyamino)-8-oxooctanoyl-L-tryptophyl-L-leucyl] *
CAS Registry Number 1126426-59-2; STN Entry Date 25 March 2009; Cyclo[D-alanyl-(2S)-2-amino-8-oxodecanoyl-L-tryptophyl-L-leucyl] *
CAS Registry Number 1126426-60-5; STN Entry Date 25 March 2009; Cyclo[L-alanyl-(2R)-2-amino-8-oxodecanoyl-L-tryptophyl-L-leucyl] *
CAS Registry Number 1126426-63-8; STN Entry Date 25 March 2009; Cyclo[N-methyl-L-alanyl-(2S)-2-amino-8-oxodecanoyl-L-tryptophyl-L-leucyl] *
CAS Registry Number 1187754-56-8; STN Entry Date 09 October 2009; Cyclo-[L-alanyl-(2S)-2-amino-8-oxodecanoyl-L-tryptophyl-(3S)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1187754-57-9; STN Entry Date 09 October 2009; Cyclo[L-alanyl-(2S)-2-amino-8-(hydroxyamino)-8-oxooctanoyl-L-trytophyl-(3S)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1187754-68-2; STN Entry Date 09 October 2009; Cyclo[(3S)-3-amino-5-methylhexanoyl-N6-acetyl-L-lysyl-(2S)-2-amino-8-oxodecanoyl-L-tryptophyl] *
CAS Registry Number 1187754-69-3; STN Entry Date 09 October 2009; 1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone, 3-(1H-indol-3-ylmethyl)-13-(2-methylproperyl)-6,9-bis(6-oxooctyl)-(3S,6S,9S,13S)- *
CAS Registry Number 1187754-77-3; STN Entry Date 09 October 2009, Cyclo[(3S)-3-amino-5-methylhexanoyl-L-phenylalanyl-(2S)-2-amino-8-oxodecanoyl-L-tryptophyl] *
CAS Registry Number 1187754-79-5; STN Entry Date 09 October 2009, Cyclo[(2S)-2-amino-8-(hydroxyamino)-8-oxooctanoyl-L-tryptophyl-(3S)-3-amino-5-methylhexanoyl-L-phenylalanyl] *
CAS Registry Number 1316753-00-0; STN Entry Date 12 August 2011; 1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone,3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-(3S,6S,9S,13S)- *
CAS Registry Number 1316753-02-2; STN Entry Date 12 August 2011; 1,4,7,10-tetraazocyclotridecane-2,5,8,1-tetrone,3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-(3S,6S,9R,13S)- *
CAS Registry Number 1349396-08-2; STN Entry Date 06 December 2011; Compound according to formula II where R8 is iso-butyl, R1 is CH2, R2 is -C(O)NH-, R3 is (CH2)5NHAc and R6 is (CH2)5C(O)CH2CH3 *
CAS Registry Number 1373504-57-4; STN Entry Date 14 May 2012; Cyclo[L-alanyl-(2S)-2-aminooctanoyl-L-tryptophyl-(3S)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1373504-63-2; STN Entry Date 14 May 2012; Cyclo[L-alanyl-L-norleucyl-L-tryptophyl-(3)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1373504-64-3; STN Entry Date 14 May 2012; Cyclo[L-alanyl-L-norvalyl-L-tryptophyl-(3S)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1373504-65-4; STN Entry Date 14 May 2012; Cyclo[(3S)-3-amino-5-methylhexanoyl-3-methoxy-L-phenylalanyl-L-norvalyl-L-tryptophyl] *
CAS Registry Number 1373504-66-5; STN Entry Date 14 May 2012; Cyclo[(3S)-3-amino-5-methylhexanoyl-L-phenylalanyl-L-norvalyl-L-tryptophyl] *
CAS Registry Number 1373504-68-7; STN Entry Date 14 May 2012; Cyclo[(3S)-3-amino-5-methylhexanoyl-(2S)-2-phenylglycyl-L-norvalyl-L-tryptophyl] *
CAS Registry Number 1373504-69-8; STN Entry Date 14 May 2012; Cyclo[3-(3-pyridinyl)-L-alanyl-L-norvalyl-L-tryptophyl-(3S)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1373504-70-1; STN Entry Date 14 May 2012; Cyclo[(3S)-3-amino-5-methylhexanoyl-L-leucyl-L-norvalyl-L-tryptophyl] *
CAS Registry Number 1373504-71-2; STN Entry Date 14 May 2012; Cyclo[D-alanyl-L-norvalyl-L-tryptophyl-(3S)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1373504-72-3; STN Entry Date 14 May 2012; Cyclo[(2S)-2-aminobutanoyl-L-norvalyl-L-tryptophyl-(3S)-3-amino-5-methylhexanoyl] *
CAS Registry Number 1373504-73-4; STN Entry Date 14 May 2012; Cyclo[(3S)-3-amino-5-methylhexanoylglycyl-L-norvalyl-L-tryptophyl] *
CAS Registry Number 1373504-74-5; STN Entry Date 14 May 2012; Cyclo[(3S)-3-amino-5-methylhexanoyl-L-asparaginyl-L-norvalyl-L-tryptophyl] *
POLLICINO, T. et al. "Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones" Gastroenterology (2006) vol. 130, pages 823-837 *

Also Published As

Publication number Publication date
EP2854832A4 (en) 2016-06-08
US20180369323A1 (en) 2018-12-27
WO2013181584A3 (en) 2014-02-13
US10143720B2 (en) 2018-12-04
HK1208823A1 (en) 2016-03-18
AU2017202675A1 (en) 2017-05-11
EP2854832A2 (en) 2015-04-08
IL235912A0 (en) 2015-01-29
KR101945578B1 (ko) 2019-02-07
JP6431478B2 (ja) 2018-11-28
CA2874828A1 (en) 2013-12-05
US20150265672A1 (en) 2015-09-24
KR20150022911A (ko) 2015-03-04
US9623071B2 (en) 2017-04-18
CN104507488A (zh) 2015-04-08
BR112014029697A2 (pt) 2017-08-08
AU2013267209A1 (en) 2014-12-18
US20170296619A1 (en) 2017-10-19
PH12014502659A1 (en) 2015-01-21
SG11201407970VA (en) 2014-12-30
WO2013181584A2 (en) 2013-12-05
JP2015518055A (ja) 2015-06-25

Similar Documents

Publication Publication Date Title
US10143720B2 (en) Modulation of hepatitis B virus cccDNA transcription
Nijampatnam et al. Recent advances in the development of HBV capsid assembly modulators
US10941121B2 (en) Human helicase DDX3 inhibitors as therapeutic agents
US20100226886A1 (en) Combinations of MTP Inhibitors with Cholesterol Absorption Inhibitors or Interferon for Treating Hepatitis C
IL250389A (en) Aliphans, Cyclops, Tropans, Tropans, Heteropranies and Converted Haloxanes Used to Treat HCV Infections
US10494404B2 (en) Quinolinium conjugates of cyclosporin
CN101247807A (zh) 噻唑化合物及使用方法
Zhang et al. Discovery of linvencorvir (RG7907), a hepatitis B virus core protein allosteric modulator, for the treatment of chronic HBV infection
Wang et al. Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors
Fan et al. Inhibitors of eukaryotic translational machinery as therapeutic agents
Vendeville et al. The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075
Hansson et al. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection
US20110117055A1 (en) Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2014049540A2 (en) Cyclic peptides and use as medicines
Hawkins et al. Potent bactericidal antimycobacterials targeting the chaperone ClpC1 based on the depsipeptide natural products ecumicin and ohmyungsamycin A
Lv et al. Design, synthesis and anti-HBV activity of NVR3-778 derivatives
US11738013B2 (en) Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
Bardiot et al. Discovery and preclinical profile of ALG-097558, a Pan-coronavirus 3CLpro inhibitor
Fan et al. Identification of Novel Amino Acid–based PROTACs Exhibiting Broad-Spectrum Antiviral Activity Against Enteroviruses
Khojasteh et al. Drug Properties
Makino et al. Discovery of a novel 9-position modified second-generation anti-HCV candidate via bioconversion and semi-synthesis of FR901459
EP3344244A1 (en) Use of indole compounds to stimulate the immune system
Rolt Development of Inhibitors of Hepatitis C Virus
NZ617102B2 (en) Substituted aliphanes, cyclophanes, heteraphanes, heterophanes and hetero-heteraphanes useful for treating hcv infections
HK1116090A (en) Thiazole compounds and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired